Metastatic Uveal Melanoma

Oncology
11
Pipeline Programs
9
Companies
29
Clinical Trials
7 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
6
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

Sanofi
ZALTRAPApproved
ziv-aflibercept
Sanofi
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2012

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
1
ZALTRAP(ZIV-Aflibercept)Phase 25 trials
Active Trials
NCT06121180Recruiting32Est. Oct 2030
NCT01688960Completed48Est. Nov 2014
NCT00532155Completed913Est. Oct 2011
+2 more trials
IDEAYA Biosciences
IDEAYA BiosciencesSOUTH SAN FRANCISCO, CA
2 programs
1
1
IDE196Phase 2/31 trial
IDE196Phase 1/21 trial
Active Trials
NCT03947385Recruiting336Est. Jun 2027
NCT05987332Active Not Recruiting420Est. Jan 2028
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
BinimetinibPhase 2Small Molecule
Pfizer
PfizerNEW YORK, NY
1 program
1
DacarbazinePhase 25 trials
Active Trials
NCT07002216Recruiting48Est. Jul 2030
NCT06377566Recruiting71Est. Apr 2027
NCT05922904Active Not Recruiting25Est. Oct 2027
+2 more trials
Delcath
DelcathQUEENSBURY, NY
1 program
1
Melphalan/HDSPhase 21 trial
Active Trials
NCT07276386Recruiting18Est. Dec 2030
Immunocore
ImmunocoreOXFORDSHIRE, United Kingdom
1 program
1
TebentafuspPhase 21 trial
Active Trials
NCT06627244Recruiting30Est. Feb 2031
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
ZIV-AfliberceptPhase 2
Novartis
NovartisBASEL, Switzerland
1 program
1
DYP688Phase 1/21 trial
Active Trials
NCT05415072Active Not Recruiting66Est. Oct 2027
Foghorn Therapeutics
1 program
1
FHD-286Phase 11 trial
Active Trials
NCT04879017TerminatedEst. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerDacarbazine
PfizerDacarbazine
PfizerDacarbazine
SanofiZIV-Aflibercept
IDEAYA BiosciencesIDE196
SanofiZIV-Aflibercept
DelcathMelphalan/HDS
PfizerDacarbazine
ImmunocoreTebentafusp
SanofiZIV-Aflibercept
PfizerDacarbazine
PfizerDacarbazine
PfizerDacarbazine
PfizerDacarbazine
PfizerDacarbazine

Showing 15 of 29 trials with date data

Clinical Trials (29)

Total enrollment: 6,231 patients across 29 trials

NCT04685616PfizerDacarbazine

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Start: Apr 2022Est. completion: Sep 20321,042 patients
Phase 3Recruiting
NCT01763164PfizerDacarbazine

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Start: Jul 2013Est. completion: Jun 2019402 patients
Phase 3Completed
NCT01712490PfizerDacarbazine

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Start: Nov 2012Est. completion: Feb 20261,334 patients
Phase 3Completed
NCT00532155SanofiZIV-Aflibercept

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Start: Sep 2007Est. completion: Oct 2011913 patients
Phase 3Completed
NCT05987332IDEAYA BiosciencesIDE196

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Start: Oct 2023Est. completion: Jan 2028420 patients
Phase 2/3Active Not Recruiting
NCT00327444SanofiZIV-Aflibercept

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Start: Jul 2006Est. completion: Oct 200958 patients
Phase 2/3Completed
NCT07276386DelcathMelphalan/HDS

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Start: Dec 2025Est. completion: Dec 203018 patients
Phase 2Recruiting
NCT07002216PfizerDacarbazine

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Start: Jul 2025Est. completion: Jul 203048 patients
Phase 2Recruiting
NCT06627244ImmunocoreTebentafusp

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Start: Feb 2025Est. completion: Feb 203130 patients
Phase 2Recruiting
NCT06121180SanofiZIV-Aflibercept

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Start: Nov 2024Est. completion: Oct 203032 patients
Phase 2Recruiting
NCT06377566PfizerDacarbazine

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Start: Apr 2024Est. completion: Apr 202771 patients
Phase 2Recruiting
NCT05922904PfizerDacarbazine

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Start: Dec 2023Est. completion: Oct 202725 patients
Phase 2Active Not Recruiting
NCT03646123PfizerDacarbazine

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Start: Jan 2019Est. completion: Aug 2024255 patients
Phase 2Terminated
NCT02505269PfizerDacarbazine

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Start: Aug 2015Est. completion: Jun 201934 patients
Phase 2Completed
NCT01920932PfizerDacarbazine

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Start: Aug 2013Est. completion: May 202877 patients
Phase 2Active Not Recruiting
NCT01716806PfizerDacarbazine

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Start: Oct 2012Est. completion: Sep 2023131 patients
Phase 2Completed
NCT01534078PfizerDacarbazine

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Start: Mar 2012Est. completion: Jan 201834 patients
Phase 2Completed
NCT01476410PfizerDacarbazine

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Start: Nov 2011Est. completion: May 202148 patients
Phase 2Unknown
NCT01551459PfizerDacarbazine

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Start: Oct 2010Est. completion: Nov 2017124 patients
Phase 2Completed
NCT00396591SanofiZIV-Aflibercept

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Start: Oct 2006Est. completion: Nov 200816 patients
Phase 2Completed
NCT00327171SanofiZIV-Aflibercept

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Start: May 2006Est. completion: Mar 2010218 patients
Phase 2Completed
NCT00284141SanofiZIV-Aflibercept

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Start: Jan 2006Est. completion: Jul 200898 patients
Phase 2Completed
NCT00070642PfizerDacarbazine

CPG 7909 Injection in Melanoma

Start: Dec 2003Est. completion: Dec 2005184 patients
Phase 2Completed
NCT05415072NovartisDYP688

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Start: Jul 2022Est. completion: Oct 202766 patients
Phase 1/2Active Not Recruiting
NCT03947385IDEAYA BiosciencesIDE196

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Start: Jun 2019Est. completion: Jun 2027336 patients
Phase 1/2Recruiting
NCT04879017Foghorn TherapeuticsFHD-286

FHD-286 in Subjects With Metastatic Uveal Melanoma

Start: May 2021Est. completion: Nov 2023
Phase 1Terminated
NCT01688960SanofiZIV-Aflibercept

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Start: Oct 2012Est. completion: Nov 201448 patients
Phase 1Completed
NCT01060904PfizerDacarbazine

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Start: Jan 2010Est. completion: Sep 201251 patients
Phase 1Completed
NCT01868451PfizerDacarbazine

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Start: May 2013Est. completion: May 2026118 patients
N/AActive Not Recruiting

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 actively recruiting trials targeting 6,231 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)